Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

49 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Diabetes NCT02210871

- 27/9/21 - 1 formulario, 2 itemgroups, 8 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function; ODM derived from: https://clinicaltrials.gov/show/NCT02210871

Eligibility Diabetes NCT00340938

- 20/9/21 - 1 formulario, 1 itemgroup, 24 items, 1 idioma
Itemgroup: Criteria
Family Management of Childhood Diabetes Study; ODM derived from: https://clinicaltrials.gov/show/NCT00340938

laboratory analysis (resurvey) SHIP-START-1 diabetes - hormones

- 3/7/21 - 1 formulario, 1 itemgroup, 12 items, 2 idiomas
Itemgroup: hormones
diabetes form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIP1.LABRE.RE_BLUT.RE_DIABETES. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

laboratory analysis (resurvey) SHIP-START-2 diabetes - diabetes

- 3/7/21 - 1 formulario, 1 itemgroup, 1 item, 2 idiomas
Itemgroup: diabetes
diabetes form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIP2.LABRE.RE_BLUT.RE_DIABETES. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

laboratory analysis (resurvey) SHIP-START-0 diabetes - diabetes

- 3/7/21 - 1 formulario, 1 itemgroup, 1 item, 2 idiomas
Itemgroup: diabetes
diabetes form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIP0.LABRE.RE_BLUT.RE_DIABETES. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Persönliches Interview SHIP-Trend-1 Diabetes

- 13/2/21 - 1 formulario, 1 itemgroup, 22 items, 1 idioma
Itemgroup: Diabetes
Diabetes form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name TREND.TREND1.INT.DIAB.DIAB. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Eligibility Diabetes NCT02505334

- 25/3/19 - 1 formulario, 2 itemgroups, 13 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02505334

Eligibility Diabetes NCT02461589

- 25/3/19 - 1 formulario, 2 itemgroups, 15 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02461589

Eligibility Diabetes NCT02453685

- 25/3/19 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02453685

Eligibility Diabetes NCT02443155

- 25/3/19 - 1 formulario, 2 itemgroups, 16 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function; ODM derived from: https://clinicaltrials.gov/show/NCT02443155

Eligibility Diabetes NCT02420262

- 24/3/19 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT02420262

Eligibility Diabetes NCT02305381

- 24/3/19 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02305381

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial